tbuckley/cabot-search huggingface dataset:
Standardizing Scoring Conventions for Crohn’s Disease Endoscopy: An International RAND/UCLA Appropriateness Study
Authors: Reena Khanna, Christopher Ma, Malcolm Hogan, Guangyong Zou, Talat Bessissow, Brian Bressler, Jean-Frédéric Colombel, Silvio Danese, Marco Daperno, James E. East, Lawrence Hookey, Edward V. Loftus, John W.D. McDonald, Remo Panaccione, Laurent Peyrin-Biroulet, Matt Rutter, Bruce E. Sands, Séverine Vermeire, Julie Rémillard, Stefanie C. McFarlane, William J. Sandborn, Geert R. D’Haens, Brian G. Feagan, Vipul Jairath
Journal: Clinical Gastroenterology and Hepatology (2023)
Comment on ‘End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB’
Authors: Antonio Bertoletti, Nina Le Bert, Anthony T. Tan, Carolina Boni, Paola Fisicaro, Carlo Ferrari, Kyong-Mi Chang, Adam J. Gehring, Georg Lauer, Mala Maini, Robert Thimme, Christoph Neumann-Haefelin
Journal: Journal of Hepatology (2023)
An observational study of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab
Authors: Zequn Tong, Yihua Zhang, Kunli Zhou, Ying Zou, Zhenlan Wu, Jiawen Chen, Zheyu Zhuang, Yifan Zhao, Ting Gong, Chao Ji
Journal: Journal of the American Academy of Dermatology (2023)
Renoprotective effects of genetically proxied fibroblast growth factor 21: Mendelian randomization, proteome-wide and metabolome-wide association study
Authors: Alice Giontella, Loukas Zagkos, Milan Geybels, Susanna C. Larsson, Ioanna Tzoulaki, Christos S. Mantzoros, Birgitte Andersen, Dipender Gill, Héléne T. Cronjé
Journal: Metabolism (2023)

BackgroundFibroblast growth factor 21 (FGF21) has demonstrated efficacy for reducing liver fat and reversing non-alcoholic steatohepatitis in phase 2 clinical trials. It is also postulated to have anti-fibrotic effects and therefore may be amenable to repurposing for the prevention and treatment of chronic kidney disease (CKD).MethodsWe leverage a missense genetic variant, rs739320 in the FGF21 gene, that associates with magnetic resonance imaging-derived liver fat as a clinically validated and biologically plausible instrumental variable for studying the effects of FGF21 analogs. Performing Mendelian randomization, we ascertain associations between instrumented FGF21 and kidney phenotypes, cardiometabolic disease risk factors, as well as the circulating proteome (Somalogic, 4907 aptamers) and metabolome (Nightingale platform, 249 metabolites).ResultsWe report consistent renoprotective associations of genetically proxied FGF21 effect, including higher glomerular filtration rates (p = 1.9 × 10−4), higher urinary sodium excretion (p = 5.1 × 10−11), and lower urine albumin-creatinine ratio (p = 3.6 × 10−5). These favorable effects translated to lower CKD risk (odds ratio per rs739320 C-allele, 0.96; 95%CI, 0.94–0.98; p = 3.2 × 10−4). Genetically proxied FGF21 effect was also associated with lower fasting insulin, waist-to-hip ratio, blood pressure (systolic and diastolic BP, p < 1.0 × 10−07) and blood lipid (low-density lipoprotein cholesterol, triglycerides and apolipoprotein B, p < 6.5 × 10−24) profiles. The latter associations are replicated in our metabolome-wide association study. Proteomic perturbations associated with genetically predicted FGF21 effect were consistent with fibrosis reduction.ConclusionThis study highlights the pleiotropic effects of genetically proxied FGF21 and supports a re-purposing opportunity for the treatment and prevention of kidney disease specifically. Further work is required to triangulate these findings, towards possible clinical development of FGF21 towards the treatment and prevention of kidney disease.
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
Authors: G. Villacampa, N.M. Tung, S. Pernas, L. Paré, C. Bueno-Muiño, I. Echavarría, S. López-Tarruella, M. Roche-Molina, M. del Monte-Millán, M. Marín-Aguilera, F. Brasó-Maristany, A.G. Waks, T. Pascual, O. Martínez-Sáez, A. Vivancos, P.F. Conte, V. Guarneri, M. Vittoria Dieci, G. Griguolo, J. Cortés, A. Llombart-Cussac, M. Muñoz, M. Vidal, B. Adamo, A.C. Wolff, A. DeMichele, P. Villagrasa, J.S. Parker, C.M. Perou, A. Fernandez-Martinez, L.A. Carey, E.A. Mittendorf, M. Martín, A. Prat, S.M. Tolaney
Journal: Annals of Oncology (2023)
The Clinical Impact and Cost-Effectiveness of Surveillance of Incidentally Detected Gastric Intestinal Metaplasia: A Microsimulation Analysis
Authors: Nikhil R. Thiruvengadam, Shashank Gupta, Seth Buller, Imad Awad, Devika Gandhi, Allison Ibarra, Gonzalo Latorre, Arnoldo Riquelme, Michael L. Kochman, Gregory Cote, Shailja C. Shah, Monica Saumoy
Journal: Clinical Gastroenterology and Hepatology (2023)
Impact of Malnutrition in Patients With Heart Failure and Secondary Mitral Regurgitation
Authors: Andrea Scotti, Augustin Coisne, Juan F. Granada, Elissa Driggin, Mahesh V. Madhavan, Zhipeng Zhou, Björn Redfors, Saibal Kar, D. Scott Lim, David J. Cohen, JoAnn Lindenfeld, William T. Abraham, Michael J. Mack, Federico M. Asch, Gregg W. Stone
Journal: Journal of the American College of Cardiology (2023)
Understanding melanoma in situ: Lentigo maligna surgical treatment terminology and guideline adherence, a targeted review
Authors: Tatiana Abrantes, Allison Robbins, Benjamin Kahn, Sara Yumeen, R. Scott Bukoski, Oliver Wisco, Leslie Robinson-Bostom, John Kawaoka, Tiffany Libby, Hayley Goldbach, Dillon Imbriano, Leonardo Lizbinski, Megan Tran, Samer Wahood, Aakash Mehta, Thomas Miner
Journal: Journal of the American Academy of Dermatology (2023)
EISA in Tandem with ICD to Form In Situ Nanofiber Vaccine for Enhanced Tumor Radioimmunotherapy
Authors: Hongjing Luo, Hongmei Cao, Haixue Jia, Yuna Shang, Jinjian Liu, Han Gui, Cuihong Yang, Chunhua Ren, Zhongyan Wang, Jianfeng Liu
Journal: Advanced Healthcare Materials (2023)

Radiotherapy (RT) can produce a vaccine effect and remodel a tumor microenvironment (TME) by inducing immunogenic cell death (ICD) and inflammation in tumors. However, RT alone is insufficient to elicit a systemic antitumor immune response owing to limited antigen presentation, immunosuppressive microenvironment, and chronic inflammation within the tumor. Here, a novel strategy is reported for the generation of in situ peptide-based nanovaccines via enzyme-induced self-assembly (EISA) in tandem with ICD. As ICD progresses, the peptide Fbp-GD FD FD pY (Fbp-pY), dephosphorylated by alkaline phosphatase (ALP) forms a fibrous nanostructure around the tumor cells, resulting in the capture and encapsulation of the autologous antigens produced by radiation. Utilizing the adjuvant and controlled-release advantages of self-assembling peptides, this nanofiber vaccine effectively increases antigen accumulation in the lymph nodes and cross-presentation by antigen-presenting cells (APCs). In addition, the inhibition of cyclooxygenase 2 (COX-2) expression by the nanofibers promotes the repolarization of M2-macrophages into M1 and reduces the number of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) required for TME remodeling. As a result, the combination of nanovaccines and RT significantly enhances the therapeutic effect on 4T1 tumors compared with RT alone, suggesting a promising treatment strategy for tumor radioimmunotherapy.
Testing for Fentanyl — Urgent Need for Practice-Relevant and Public Health Research
Authors: Nora D. Volkow, Robert M. Califf, Marta Sokolowska, Lawrence A. Tabak, Wilson M. Compton
Journal: New England Journal of Medicine (2023)

The reach of fentanyl and other substances is expanding. Fentanyl test strips can detect one specific agent, and lessons from their use may inform practices for new drug-related crises.
Reply: Is lifestyle modification effective for individuals with high fibrosis-4 index without an additional second-tier test?
Authors: Kinpritma Sangha, Stephanie T. Chang, Ramsey Cheung, Vibhas S. Deshpande
Journal: Hepatology (2023)

Sangha, Kinpritma; Chang, Stephanie T.; Cheung, Ramsey; Deshpande, Vibhas S. Author Information
Analysis of individual patient data in patients with HCC treated with immunotherapy: A step forward for clinical trial design
Authors: Matthias Pinter, Maria Reig, Giuseppe Cabibbo
Journal: Hepatology (2023)

1Division of Gastroenterology & Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria 2Barcelona Clinic Liver Cancer (BCLC) Group, Liver Oncology Unit, Liver Unit, Hospital Clinic of Barcelona, Barcelona. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain 3Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, PROMISE, Gastroenterology & Hepatology Unit, University of Palermo, Palermo, Italy Correspondence Matthias Pinter, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. Email: [email protected]
Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making
Authors: Renumathy Dhanasekaran, Hiroyuki Suzuki, Lea Lemaitre, Naoto Kubota, Yujin Hoshida
Journal: Hepatology (2023)

Liver cancer, primarily HCC, exhibits highly heterogeneous histological and molecular aberrations across tumors and within individual tumor nodules. Such intertumor and intratumor heterogeneities may lead to diversity in the natural history of disease progression and various clinical disparities across the patients. Recently developed multimodality, single-cell, and spatial omics profiling technologies have enabled interrogation of the intertumor/intratumor heterogeneity in the cancer cells and the tumor immune microenvironment. These features may influence the natural history and efficacy of emerging therapies targeting novel molecular and immune pathways, some of which had been deemed undruggable. Thus, comprehensive characterization of the heterogeneities at various levels may facilitate the discovery of biomarkers that enable personalized and rational treatment decisions, and optimize treatment efficacy while minimizing the risk of adverse effects. Such companion biomarkers will also refine HCC treatment algorithms across disease stages for cost-effective patient management by optimizing the allocation of limited medical resources. Despite this promise, the complexity of the intertumor/intratumor heterogeneity and ever-expanding inventory of therapeutic agents and regimens have made clinical evaluation and translation of biomarkers increasingly challenging. To address this issue, novel clinical trial designs have been proposed and incorporated into recent studies. In this review, we discuss the latest findings in the molecular and immune landscape of HCC for their potential and utility as biomarkers, the framework of evaluation and clinical application of predictive/prognostic biomarkers, and ongoing biomarker-guided therapeutic clinical trials. These new developments may revolutionize patient care and substantially impact the still dismal HCC mortality.
Letter to the Editor: Dynamic risk profiling of HCC recurrence after curative intent liver resection
Authors: Muhammad Zain ul abideen Awan, Tirath Patel
Journal: Hepatology (2023)

1Institute: Punjab medical college, Faisalabad, Department: Gastroenterology 2Institute: American University of Antigua, Department: General Surgery City: Antigua and Barbuda, Jabberwock Rd, Osbourn, Antigua and Barbuda Declaration: None Correspondence Muhammad Zain ul abideen Awan, Punjab Medical College, Neurology. Email: [email protected]
Impact of adjuvant radiation therapy on survival and recurrence in patients with stage I-III Merkel cell carcinoma: A retrospective study of 312 patients
Authors: Cassandre Pottier, Antoine Marchand, Thibault Kervarrec, Yannick Le Corre, Charlée Nardin, François Aubin, Ewa Wierzbicka-Hainaut, Julie Cassecuel, Brigitte Dreno, Guido Bens, Nathalie Beneton, Delphine Legoupil, Monica Dinulescu, Philippe Saiag, Astrid Fily-Blom, Mahtab Samimi
Journal: Journal of the American Academy of Dermatology (2023)
Silver‐Containing Biomaterials for Biomedical Hard Tissue Implants
Authors: Huifeng Shao, Tao Zhang, Youping Gong, Yong He
Journal: Advanced Healthcare Materials (2023)

Bacterial infection caused by biomaterials is a very serious problem in the clinical treatment of implants. The emergence of antibiotic resistance has prompted other antibacterial agents to replace traditional antibiotics. Silver is rapidly developing as an antibacterial candidate material to inhibit bone infections due to its significant advantages such as high antibacterial timeliness, high antibacterial efficiency, and less susceptibility to bacterial resistance. However, silver has strong cytotoxicity, which can cause inflammatory reactions and oxidative stress, thereby destroying tissue regeneration, making the application of silver-containing biomaterials extremely challenging. In this paper, the application of silver in biomaterials is reviewed, focusing on the following three issues: 1) how to ensure the excellent antibacterial properties of silver, and not easy to cause bacterial resistance; 2) how to choose the appropriate method to combine silver with biomaterials; 3) how to make silver-containing biomaterials in hard tissue implants have further research. Following a brief introduction, the discussion focuses on the application of silver-containing biomaterials, with an emphasis on the effects of silver on the physicochemical properties, structural properties, and biological properties of biomaterials. Finally, the review concludes with the authors' perspectives on the challenges and future directions of silver in commercialization and in-depth research.
A major research gap: The use of anticoagulants in cirrhosis
Authors: Marco Senzolo, Juan Carlos Garcia-Pagan
Journal: Journal of Hepatology (2023)

Historically, anticoagulants were contraindicated in patients with cirrhosis owing to concerns about bleeding risks. However, recent studies have shown that patients with cirrhosis are not naturally anticoagulated and are at increased risk of prothrombotic events, such as portal venous thrombosis. In this article, we review preclinical and clinical data on the effects of anticoagulants in cirrhosis, including their potential benefits in reducing liver fibrosis, portal hypertension, and improving survival. Despite promising preclinical evidence, clinical translation has proven challenging. Nevertheless, we discuss the use of anticoagulation in specific clinical scenarios, such as patients with atrial fibrillation and portal vein thrombosis, and highlight the need for further research, including randomised-controlled trials, to determine the optimal role of anticoagulants in the management of patients with cirrhosis.
Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis
Authors: Laure Elkrief, Nathalie Ganne-Carrié, Hana Manceau, Marion Tanguy, Shantha Ram Valainathan, Alix Riescher-Tuczkiewicz, Louise Biquard, Nathalie Barget, Cendrine Chaffaut, Alexandre Louvet, Valérie Paradis, Marianne Ziol, Rikke Bæk, Malene Møller Jørgensen, Guillaume Van Niel, Pierre-Michael Coly, Adel Hammoutène, Fanny Dujardin, Katell Peoc’h, Thierry Poynard, Sylvie Chevret, Pierre-Emmanuel Rautou
Journal: Journal of Hepatology (2023)
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
Authors: Uwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini, Amer M Zeidan, Rami S Komrokji, Jake Shortt, David Valcarcel, Anna Jonasova, Sophie Dimicoli-Salazar, Ing Soo Tiong, Chien-Chin Lin, Jiahui Li, Jennie Zhang, Ana Carolina Giuseppi, Sandra Kreitz, Veronika Pozharskaya, Karen L Keeperman, Shelonitda Rose, Jeevan K Shetty, Sheida Hayati, Sadanand Vodala, Thomas Prebet, Andrius Degulys, Stefania Paolini, Thomas Cluzeau, Pierre Fenaux, Guillermo Garcia-Manero
Journal: The Lancet (2023)
Prevention and treatment of inflammatory arthritis with traditional Chinese medicine: Underlying mechanisms based on cell and molecular targets
Authors: Wenhao Li, Lei Yu, Wenming Li, Gaoran Ge, Yong Ma, Long Xiao, Yusen Qiao, Wei Huang, Wenli Huang, Minggang Wei, Zhirong Wang, Jiaxiang Bai, Dechun Geng
Journal: Ageing Research Reviews (2023)
Curcumin-QingDai Combination for Patients With Active Ulcerative Colitis: A Randomized, Double-Blinded, Placebo-Controlled Trial
Authors: Shomron Ben-Horin, Nir Salomon, Georgios Karampekos, Nikos Viazis, Adi Lahat, Bella Ungar, Rami Eliakim, Rafael Kuperstein, Ofra Kriger-Sharabi, Hilla Reiss-Mintz, Henit Yanai, Iris Dotan, Eran Zittan, Nitsan Maharshak, Ayal Hirsch, Michal Weitman, Gerassimos J. Mantzaris, Uri Kopylov
Journal: Clinical Gastroenterology and Hepatology (2023)
Towards clinical applicability and computational efficiency in automatic cranial implant design: An overview of the AutoImplant 2021 cranial implant design challenge
Authors: Jianning Li, David G. Ellis, Oldřich Kodym, Laurèl Rauschenbach, Christoph Rieß, Ulrich Sure, Karsten H. Wrede, Carlos M. Alvarez, Marek Wodzinski, Mateusz Daniol, Daria Hemmerling, Hamza Mahdi, Allison Clement, Evan Kim, Zachary Fishman, Cari M. Whyne, James G. Mainprize, Michael R. Hardisty, Shashwat Pathak, Chitimireddy Sindhura, Rama Krishna Sai S. Gorthi, Degala Venkata Kiran, Subrahmanyam Gorthi, Bokai Yang, Ke Fang, Xingyu Li, Artem Kroviakov, Lei Yu, Yuan Jin, Antonio Pepe, Christina Gsaxner, Adam Herout, Victor Alves, Michal Španěl, Michele R. Aizenberg, Jens Kleesiek, Jan Egger
Journal: Medical Image Analysis (2023)
Hepatocellular Carcinoma Incidence Threshold for Surveillance in Virologically Cured Hepatitis C Individuals
Authors: Jagpreet Chhatwal, Ali Hajjar, Peter P. Mueller, Gizem Nemutlu, Neeti Kulkarni, Mary Linton B. Peters, Fasiha Kanwal
Journal: Clinical Gastroenterology and Hepatology (2023)
Viral emissions into the air and environment after SARS-CoV-2 human challenge: a phase 1, open label, first-in-human study
Authors: Jie Zhou, Anika Singanayagam, Niluka Goonawardane, Maya Moshe, Fiachra P Sweeney, Ksenia Sukhova, Ben Killingley, Mariya Kalinova, Alex J Mann, Andrew P Catchpole, Michael R Barer, Neil M Ferguson, Christopher Chiu, Wendy S Barclay
Journal: The Lancet Microbe (2023)

Effectively implementing strategies to curb SARS-CoV-2 transmission requires understanding who is contagious and when. Although viral load on upper respiratory swabs has commonly been used to infer contagiousness, measuring viral emissions might be more accurate to indicate the chance of onward transmission and identify likely routes. We aimed to correlate viral emissions, viral load in the upper respiratory tract, and symptoms, longitudinally, in participants who were experimentally infected with SARS-CoV-2.
Injectable, Antibacterial, and Hemostatic Tissue Sealant Hydrogels
Authors: Reihaneh Haghniaz, Hossein Montazerian, Atiya Rabbani, Avijit Baidya, Brent Usui, Yangzhi Zhu, Maryam Tavafoghi, Fazli Wahid, Han‐Jun Kim, Amir Sheikhi, Ali Khademhosseini
Journal: Advanced Healthcare Materials (2023)

Hemorrhage and bacterial infections are major hurdles in the management of life-threatening surgical wounds. Most bioadhesives for wound closure lack sufficient hemostatic and antibacterial properties. Furthermore, they suffer from weak sealing efficacy, particularly for stretchable organs, such as the lung and bladder. Accordingly, there is an unmet need for mechanically robust hemostatic sealants with simultaneous antibacterial effects. Here, an injectable, photocrosslinkable, and stretchable hydrogel sealant based on gelatin methacryloyl (GelMA), supplemented with antibacterial zinc ferrite (ZF) nanoparticles and hemostatic silicate nanoplatelets (SNs) for rapid blood coagulation is nanoengineered. The hydrogel reduces the in vitro viability of Staphylococcus aureus by more than 90%. The addition of SNs (2% w/v) and ZF nanoparticles (1.5 mg mL
Distinct immune microenvironment of lung adenocarcinoma in never-smokers from smokers
Authors: Wenxin Luo, Zhen Zeng, Yang Jin, Lan Yang, Ting Fan, Zhoufeng Wang, Yitong Pan, Ying Yang, Menglin Yao, Yangqian Li, Xue Xiao, Gang Wang, Chengdi Wang, Shuai Chang, Guowei Che, Li Zhang, Yalun Li, Yong Peng, Weimin Li
Journal: Cell Reports Medicine (2023)

Lung cancer in never-smokers (LCINS) presents clinicopathological and molecular features distinct from that in smokers. Tumor microenvironment (TME) plays important roles in cancer progression and therapeutic response. To decipher the difference in TME between never-smoker and smoker lung cancers, we conduct single-cell RNA sequencing on 165,753 cells from 22 treatment-naive lung adenocarcinoma (LUAD) patients. We find that the dysfunction of alveolar cells induced by cigarette smoking contributes more to the aggressiveness of smoker LUADs, while the immunosuppressive microenvironment exerts more effects on never-smoker LUADs' aggressiveness. Moreover, the SPP1hi pro macrophage is identified to be another independent source of monocyte-derived macrophage. Importantly, higher expression of immune checkpoint CD47 and lower expression of major histocompatibility complex (MHC)-I in cancer cells of never-smoker LUADs imply that CD47 may be a better immunotherapy target for LCINS. Therefore, this study reveals the difference of tumorigenesis between never-smoker and smoker LUADs and provides a potential immunotherapy strategy for LCINS.
An integrative review on the acceptance of artificial intelligence among healthcare professionals in hospitals
Authors: Sophie Isabelle Lambert, Murielle Madi, Saša Sopka, Andrea Lenes, Hendrik Stange, Claus-Peter Buszello, Astrid Stephan
Journal: npj Digital Medicine (2023)

Abstract Artificial intelligence (AI) in the domain of healthcare is increasing in prominence. Acceptance is an indispensable prerequisite for the widespread implementation of AI. The aim of this integrative review is to explore barriers and facilitators influencing healthcare professionals’ acceptance of AI in the hospital setting. Forty-two articles met the inclusion criteria for this review. Pertinent elements to the study such as the type of AI, factors influencing acceptance, and the participants’ profession were extracted from the included studies, and the studies were appraised for their quality. The data extraction and results were presented according to the Unified Theory of Acceptance and Use of Technology (UTAUT) model. The included studies revealed a variety of facilitating and hindering factors for AI acceptance in the hospital setting. Clinical decision support systems (CDSS) were the AI form included in most studies ( n = 21). Heterogeneous results with regard to the perceptions of the effects of AI on error occurrence, alert sensitivity and timely resources were reported. In contrast, fear of a loss of (professional) autonomy and difficulties in integrating AI into clinical workflows were unanimously reported to be hindering factors. On the other hand, training for the use of AI facilitated acceptance. Heterogeneous results may be explained by differences in the application and functioning of the different AI systems as well as inter-professional and interdisciplinary disparities. To conclude, in order to facilitate acceptance of AI among healthcare professionals it is advisable to integrate end-users in the early stages of AI development as well as to offer needs-adjusted training for the use of AI in healthcare and providing adequate infrastructure.
Reply
Authors: Samantha A. Banks, M. Tariq Bhatti, Ronald S. Go, Jithma P. Abeykoon, Aldo A. Acosta-Medina, Antonious Z. Hazim, Gaurav Goyal, Jason R. Young, Matthew J. Koster, Robert Vassallo, Jay H. Ryu, Caroline J. Davidge-Pitts, Aishwarya Ravindran, Julio C. Sartori Valinotti, N. Nora Bennani, Mithun V. Shah, Karen L. Rech, James A. Garrity, W. Oliver Tobin
Journal: Ophthalmology (2023)